bioAffinity Technologies, Inc. (BIAFW)

Market Cap	3.58M
Revenue (ttm)	9.36M
Net Income (ttm)	-9.04M
Shares Out	17.91M
EPS (ttm)	-0.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	450
Open	0.1201
Previous Close	0.1711
Day's Range	0.1200 - 0.1386
52-Week Range	0.1500 - 0.1711
Beta	3.47
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 28, 2025

About BIAFW

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2014
• Employees: 57
• Stock Exchange: NASDAQ
• Ticker Symbol: BIAFW
• Website: https://www.bioaffinitytech.com

Financial Performance

In 2024, bioAffinity Technologies's revenue was $9.36 million, an increase of 269.68% compared to the previous year's $2.53 million. Losses were -$9.04 million, 13.9% more than in 2023.